RIP assays with NF90 specific antibody revealed the significant enrichment of pri-miR-145 in both CHL-1 and SK-MEL-2 cells (Figures 5D, E), supporting the binding of NF90 to pri-miR-145 in melanoma. This evidence concerns the gene ILF3 and melanoma.